Cdsco

Cdsco News

India's drug regulatory agency's bribery controversy a blessing in disguise
India

India's drug regulatory agency's bribery controversy a blessing in disguise

The latest allegations could be indicative of years old, deeply rooted tradition of CDSCO — the office of which is jokingly called as ‘snake pit’ by pharma industry officials

All you need to know about Biocon's Insulin Aspart, which is at the centre of a bribery controversy
Health

All you need to know about Biocon's Insulin Aspart, which is at the centre of a bribery controversy

‘Insulin Aspart’ injection is at the center of the entire controversy as it is alleged that a bribe was given to Central Drugs Standard Control Organisation (CDSCO)’s official to waive off the Phase 3 clinical trial of the medicine in India

Is Centre giving ‘expired’ COVID-19 vaccines to teenagers? A look at the shelf life of a jab and what the row is about
India

Is Centre giving ‘expired’ COVID-19 vaccines to teenagers? A look at the shelf life of a jab and what the row is about

The Centre on Monday issued a clarification, calling reports of expired Covaxin doses being administered to children aged 15-18 ‘misleading and false’

Bharat Biotech submits vaccine data for phase 2/3 trials on children between 2-18 years to DCGI
India

Bharat Biotech submits vaccine data for phase 2/3 trials on children between 2-18 years to DCGI

The paediatric Covaxin is similar to the one administered to adults - two doses of the vaccine given 28 days apart.

Bharat Biotech’s intranasal vaccine for COVID-19: Everything we know so far about BBV154
India

Bharat Biotech’s intranasal vaccine for COVID-19: Everything we know so far about BBV154

The intranasal vaccine BBV154 is being tested to check if it prevents infection, halts person-to-person transmission, and progression of COVID-19.

Moderna's COVID-19 vaccine gets approval for restricted emergency use, confirms Centre
India

Moderna's COVID-19 vaccine gets approval for restricted emergency use, confirms Centre

Earlier news agency PTI had reported that the DCGI has granted permission to Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country.

Centre discontinues Remdesivir allocation to states, says supply much more than demand
India

Centre discontinues Remdesivir allocation to states, says supply much more than demand

Mandaviya said the production of Remdesivir has been increased ten times from just around 33,000 vials per day on 11 April to around 3,50,000 vials per day as of today

Eli Lilly inks pacts for COVID-19 drug Baricitinib with Torrent Pharma, Dr Reddy's and MSN Labs
India

Eli Lilly inks pacts for COVID-19 drug Baricitinib with Torrent Pharma, Dr Reddy's and MSN Labs

The drug Baricitinib will be used in combination with Remdesivir for the treatment of patients requiring supplemental oxygen, invasive mechanical ventilation, Eli Lilly and Company said in a statement

SEC recommends Bharat Biotech’s Covaxin phase 2, 3 clinical trials on 2- to 18-year-olds
India

SEC recommends Bharat Biotech’s Covaxin phase 2, 3 clinical trials on 2- to 18-year-olds

The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur.

Over 160 L COVID-19 vaccine doses procured so far, but beneficiaries below target due to hesitancy, govt tells LS
India

Over 160 L COVID-19 vaccine doses procured so far, but beneficiaries below target due to hesitancy, govt tells LS

Giving out the details of the number of vaccines already procured by the government, Minister of State for Health Ashwini Choubey said the total cost of procurement of above mentioned doses of vaccines is Rs 350.25 crore

Coronavirus News Updates: COVID-19 expert panel recommends emergency use authorisation for Bharat Biotech's COVAXIN
Health

Coronavirus News Updates: COVID-19 expert panel recommends emergency use authorisation for Bharat Biotech's COVAXIN

Coronavirus News LIVE Updates: Covaxin has been indigenously developed by Bharat Biotech in collaboration with the ICMR

SEC recommends Bharat Biotech's COVAXIN for emergency use as India tests its vaccine delivery system
India

SEC recommends Bharat Biotech's COVAXIN for emergency use as India tests its vaccine delivery system

The recommendation for Bharat Biotech's vaccine came a day after the COVID-19 expert panel cleared the Serum Institute of India's emergency use authorisation application for the Oxford-AstraZeneca vaccine 'Covishield'

COVID-19 expert panel recommends Bharat Biotech jab COVAXIN for emergency use authorisation
India

COVID-19 expert panel recommends Bharat Biotech jab COVAXIN for emergency use authorisation

The Subject Expert Committee (SEC) on COVID-19 of the CDSCO noted that the vaccine is an inactivated whole virion, coronavirus vaccine, having the potential to target mutated coronavirus strains, a source told PTI

COVID-19 dry runs: From vaccination rooms to Co-WIN app, here's how mock immunisation drive is held across India
India

COVID-19 dry runs: From vaccination rooms to Co-WIN app, here's how mock immunisation drive is held across India

The primary objective of the dry run is to assess the operational feasibility of using the Co-WIN application in a field environment. The app was specially designed to keep a track of Covid-19 vaccination programme and allow Indian citizens to apply for a Covid-19 vaccine shot

COVID-19 panel recommends SII's Covishield for emergency use; new cases remain under 30,000 for 19th day
India

COVID-19 panel recommends SII's Covishield for emergency use; new cases remain under 30,000 for 19th day

The daily new coronavirus infections in India remained below 30,000 for the 19th consecutive day on Friday, taking the total caseload to 1,02,86,709

Indian regulator seeks more time as UK authorises Oxford COVID-19 jab; six things about cheap, easy to store vaccine
India

Indian regulator seeks more time as UK authorises Oxford COVID-19 jab; six things about cheap, easy to store vaccine

In India, a decision on emergency usage of the vaccine, which is being manufactured by Pune-based Serum Institute of India, is likely to come next year with the Subject Expert Committee (SEC) on COVID-19 seeking more time today

CDSCO asks Bharat Biotech to submit complete immunogenicity data of Phase 2 trial of COVID-19 vaccine
India

CDSCO asks Bharat Biotech to submit complete immunogenicity data of Phase 2 trial of COVID-19 vaccine

The vaccine candidate, 'Covaxin', is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research

COVID-19 vaccine: Serum Institute of India to begin Phase 2 trial of Oxford-Astrazeneca candidate today
India

COVID-19 vaccine: Serum Institute of India to begin Phase 2 trial of Oxford-Astrazeneca candidate today

The DCGI on 3 August had given nod to the Pune Serum Institute of India for conducting phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate

Serum Institute asked to revise protocols for Phase 2, 3 trials of Oxford COVID-19 vaccine candidate
science

Serum Institute asked to revise protocols for Phase 2, 3 trials of Oxford COVID-19 vaccine candidate

The CDSCO expert panel also recommended that Pune-based firm's proposed clinical trial sites be distributed across India

India's vaccine scenario: A success story marred with regulatory lapses
Health

India's vaccine scenario: A success story marred with regulatory lapses

Though the Minister of State for Health and Family Welfare has a National Vaccine Policy document, it does not address all the problems associated with UIP.